<DOC>
	<DOCNO>NCT01025115</DOCNO>
	<brief_summary>The purpose study assess efficacy Diamel administration treatment Metabolic Syndrome . The duration double-blind placebo control phase 3 clinical trial 12 month .</brief_summary>
	<brief_title>Diamel Treatment Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>Metabolic syndrome diagnosis accord WHO definition , without glucose intolerance . Signed informed consent Type 1 diabetes Type 2 diabetes treat oral hypoglycemic drug and/or insulin Other disease associate insulin resistance ( eg . Acromegalia , endogenous hypercortisolism , etc ) Neuropathies hepatic condition diagnose biochemically clinical exam . Mild severe heart condition ( eg . heart failure , ischemic cardiopathy ) Sepsis condition could potentially interfere treatment Any treatment could potentially interfere treatment Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Dietary supplement</keyword>
	<keyword>Diamel</keyword>
	<keyword>Metabolic Syndrome</keyword>
</DOC>